If successful, it will be the first noninvasive screening test for gastric cancer: the second
deadliest cancer worldwide and one with a particularly high prevalence among Asian populations.
«Injectable immunotherapies that use programmable biomaterials as a powerful vehicle to deliver targeted treatment and preventative care could help fight a whole range of
deadly infections, including common
worldwide killers like HIV and Ebola, as well as
cancer,» said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D. who is also Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children's Hospital, and Professor of Bioengineering at Harvard SEAS.